By Professor Michael Leonard Friedlander

Book Chapters

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 23, http://dx.doi.org/10.1002/9781119000822.hfcm105.pub2

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 18, http://dx.doi.org/10.1002/9781119000822.hfcm106.pub2

Christie EL; Freimund AE; Fereday S; Alsop K; Hoang T; Pishas K; Au-Yeung G; Friedlander M; Bowtell DD, 2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3

Amant F; Hensley M; Pautier P; Friedlander M; Sagae S; Fujiwara K; Berton Rigaud D; Lorusso D; Ray-Coquard I, 2020, 'Management of Rare Uterine Malignant Tumors', in Management of Endometrial Cancer, Springer International Publishing, pp. 277 - 312, http://dx.doi.org/10.1007/978-3-319-64513-1_19

Berek JS; Friedlander ML; Bast RC, 2017, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 27, http://dx.doi.org/10.1002/9781119000822.hfcm105

Berek JS; Friedlander ML; Bast RC, 2017, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 17, http://dx.doi.org/10.1002/9781119000822.hfcm106

Friedlander ML; Markman M, 2014, 'Chemotherapy', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 58 - 84

Berek JS; Friedlander ML; Hacker NF, 2014, 'Epithelial ovarian, fallopian tube, and peritoneal cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 464 - 529

Berek JS; Friedlander ML; Hacker NF, 2014, 'Germ cell and nonepithelial ovarian cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 530 - 559

Hacker NF; Friedlander ML, 2014, 'Uterine cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 390 - 442

Friedlander M; Thigpen JT, 2014, 'Response as a measure of treatment efficacy in clinical trials: Should recist be abandoned?', in Controversies in the Management of Gynecological Cancers, pp. 91 - 100, http://dx.doi.org/10.1007/978-0-85729-910-9_9

Berek JS; Longacre T; Friedlander M, 2011, 'Ovarian, Fallopian Tube and Peritoneal Cancer', in Berek JS (ed.), Berek and Novak's Gynecology, edn. 15th, Royal College of Obstetricians and Gynaecologists, UK, pp. 1350 - 1427

Gainford M; Friedlander M, 2011, 'Squamous Cell Carcinomas Arising From Dermoids', in Reed N; Green JA; Gershenson DM; Siddiqui N; Connor R (ed.), Rare and Uncommon Gynecological Cancers, Springer, USA, pp. 131 - 134

Hacker NF; Friedlander ML, 2010, 'Breast Disease: A Gynecologic Perspective', in Hacker &amp Moore's Essentials of Obstetrics and Gynecology, Elsevier, pp. 326 - 331, http://dx.doi.org/10.1016/b978-1-4160-5940-0.00029-1

Friedlander ML; Gershenson D; Hacker NF; Arjun G; Smitj ; Barber HM, 1997, 'Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers.', in Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers., edn. Original, Mercel Dekker, New York, pp. 263 - 270

Journal articles

Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M, 2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE, 2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43, http://dx.doi.org/10.1016/j.tranon.2024.101914

Ganz PA; Bandos H; Španić T; Friedman S; Müller V; Kuemmel S; Delaloge S; Brain E; Toi M; Yamauchi H; De Dueñas EM; Armstrong A; Im SA; Song CG; Zheng H; Sarosiek T; Sharma P; Geng C; Fu P; Rhiem K; Frauchiger-Heuer H; Wimberger P; T'Kint De Roodenbeke D; Liao N; Goodwin A; Chakiba-Brugère C; Friedlander M; Lee KS; Giacchetti S; Takano T; Henao-Carrasco F; Virani S; Valdes-Albini F; Domchek SM; Bane C; McCarron EC; Mita M; Rossi G; Rastogi P; Fielding A; Gelber RD; Scheepers ED; Cameron D; Garber J; Geyer CE; Tutt ANJ, 2024, 'Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer', Journal of Clinical Oncology, 42, pp. 1288 - 1300, http://dx.doi.org/10.1200/JCO.23.01214

Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK; Khoon Lee C; You B; Paoletti X; Glasspool R; Friedlander M; Scott C; Mirza M; Pujade Lauraine E; Ledermann J; Antill Y; Mileshkin L; Ethier JL; Bookman M; Gourley C, 2024, 'Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor', Journal of Clinical Oncology, 42, pp. 1301 - 1310, http://dx.doi.org/10.1200/JCO.23.01182

Diéras V; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Loirat D; Ratajczak C; Adamu H; Girardi V; Arun BK, 2024, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial', European Journal of Cancer, 200, http://dx.doi.org/10.1016/j.ejca.2024.113580

Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK, 2024, 'Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer', British Journal of Cancer, 130, pp. 425 - 433, http://dx.doi.org/10.1038/s41416-023-02528-z

Woodford R; Zhou D; Kok P-S; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK, 2024, 'Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.', JCO Precis Oncol, 8, pp. e2300296, http://dx.doi.org/10.1200/PO.23.00296

Burdett NL; Willis MO; Pandey A; Fereday S; AOCS Study Group ; DeFazio A; Bowtell DDL; Christie EL, 2023, 'Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.', Sci Rep, 13, pp. 21884, http://dx.doi.org/10.1038/s41598-023-48153-x

Friedlander M; Mileshkin L; Lombard J; Frentzas S; Gao B; Wilson M; Meniawy T; Baron-Hay S; Briscoe K; McCarthy N; Fountzilas C; Cervantes A; Ge R; Wu J; Spira A, 2023, 'Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial', British Journal of Cancer, 129, pp. 797 - 810, http://dx.doi.org/10.1038/s41416-023-02349-0

Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; Sahlberg KK; Børresen-Dale AL; Gram IT; Olsen KS; Engebråten O; Naume B; Geisler J; Grenaker Alnæs GI; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; Clarke C; Marsh D; Scott R; Baxter R; Yip D; Carpenter J; Davis A; Pathmanathan N; Simpson P; Graham JD; Sachchithananthan M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; DeFazio A, 2023, 'Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival', Cancer Medicine, 12, pp. 16142 - 16162, http://dx.doi.org/10.1002/cam4.6272

Johnston EA; Ibiebele TI; Friedlander ML; Grant PT; van der Pols JC; Webb PM, 2023, 'Association of Protein Intake with Recurrence and Survival Following Primary Treatment of Ovarian Cancer', American Journal of Clinical Nutrition, 118, pp. 50 - 58, http://dx.doi.org/10.1016/j.ajcnut.2023.05.002

Praiss AM; Miller A; Smith J; Lichtman SM; Bookman M; Aghajanian C; Sabbatini P; Backes F; Cohn DE; Argenta P; Friedlander M; Goodheart MJ; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray H; Secord AA; Van Le L; O'Cearbhaill RE, 2023, 'Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study', Gynecologic Oncology, 174, pp. 213 - 223, http://dx.doi.org/10.1016/j.ygyno.2023.05.013

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.', Journal of Clinical Oncology, 41, pp. 5561 - 5561, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5561

May T; Bernardini M; Lheureux S; Aben KKH; Bandera EV; Beckmann MW; Benitez J; Berchuck A; Bjørge L; Carney ME; Cramer DW; Defazio A; Dörk T; Eccles DM; Friedlander M; García MJ; Goode EL; Hein A; Jensen A; Johnatty S; Kennedy CJ; Kiemeney LA; Kjær SK; Kupryjanczyk J; Matsuo K; McGuire V; Modugno F; Paddock LE; Pejovic T; Phelan CM; Riggan MJ; Rodriguez-Antona C; Rothstein JH; Sieh W; Song H; Terry KL; Altena AMV; Vanderstichele A; Vergote I; Thomsen LCV; Webb PM; Wentzensen N; Wilkens LR; Ziogas A; Jiang H; Tone A, 2023, 'Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis', CMAJ. Canadian Medical Association Journal, 66, pp. E310 - E320, http://dx.doi.org/10.1503/cjs.017020

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031

Ngoi NYL; Sun H; Choi CH; Heong V; Ow SGW; Chay WY; Kim HS; Goss G; Goh JC; Lin M; Lim D; Kim J-W; Friedlander M; Tai BC; Kim K; Tan DSP, 2023, 'Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.', Journal of Clinical Oncology, 41, pp. e17564 - e17564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17564

Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM, 2023, 'The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study', Gynecologic Oncology, 173, pp. 130 - 137, http://dx.doi.org/10.1016/j.ygyno.2023.03.018

Majidi A; Na R; Jordan SJ; DeFazio A; Obermair A; Friedlander M; Grant P; Webb PM, 2023, 'Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study', Journal of the National Cancer Institute, 115, pp. 570 - 577, http://dx.doi.org/10.1093/jnci/djac239

Pitiyarachchi O; Lee YC; Sim HW; Srirangan S; Mapagu C; Kirk J; Harnett PR; Balleine RL; Bowtell DDL; Samimi G; Brand AH; Marsh DJ; Beale P; Anderson L; Bouantoun N; Provan P; Ramus SJ; DeFazio A; Friedlander M, 2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638

Solomon B; Gao B; Subbiah V; Millward M; Rosen L; Desai J; Sbar EI; Collins N; Hoang T; Song X; Shao W; Jaggi J; Edris B; Ramachandran P; Luo L; Friedlander M, 2023, 'Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors', Cancer Research, 83, pp. CT033 - CT033, http://dx.doi.org/10.1158/1538-7445.am2023-ct033

Hayes S; Obermair A; Mileshkin L; Davis A; Gordon LG; Eakin E; Janda M; Beesley VL; Barnes EH; Spence RR; Sandler C; Jones T; Vagenas D; Webb P; Andrews J; Brand A; Lee YC; Friedlander M; Pumpa K; O'Neille H; Williams M; Stockler M, 2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-067925

Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; Sahlberg KK; Børresen-Dale AL; Gram IT; Olsen KS; Engebråten O; Naume B; Geisler J; OSBREAC ; Grenaker Alnæs GI; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; DeFazio A; Delatycki M; Dickson R; Dixon J; Edkins T; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C, 2023, 'The impact of coding germline variants on contralateral breast cancer risk and survival', American Journal of Human Genetics, 110, pp. 475 - 486, http://dx.doi.org/10.1016/j.ajhg.2023.02.003

Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB, 2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834

You B; Sehgal V; Hosmane B; Huang X; Ansell PJ; Dinh MH; Bell-Mcguinn K; Luo X; Fleming GF; Friedlander M; Bookman MA; Moore KN; Steffensen KD; Coleman RL; Swisher EM, 2023, 'CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis from the VELIA/GOG-3005 Study', Journal of Clinical Oncology, 41, pp. 107 - 116, http://dx.doi.org/10.1200/JCO.22.00430

Cohen PA; Webb PM; King M; Obermair A; Gebski V; Butow P; Morton R; Lawson W; Yates P; Campbell R; Meniawy T; McMullen M; Dean A; Goh J; McNally O; Mileshkin L; Beale P; Beach R; Hill J; Dixon C; Hegarty S; Codde J; Ives A; Lee YC; Brand A; Mellon A; Bilic S; Black I; Jeffares S; Friedlander M, 2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2021-002999

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martí A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See ML; Moore KN, 2023, 'Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical and Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/OGX.0000000000001120

Meagher NS; Hamilton P; Milne K; Thornton S; Harris B; Weir A; Alsop J; Bisinoto C; Brenton JD; Brooks-Wilson A; Chiu DS; Cushing-Haugen KL; Fereday S; Garsed DW; Gayther SA; Gentry-Maharaj A; Gilks B; Jimenez-Linan M; Kennedy CJ; Le ND; Piskorz AM; Riggan MJ; Shah M; Singh N; Talhouk A; Widschwendter M; Bowtell DDL; Candido dos Reis FJ; Cook LS; Fortner RT; García MJ; Harris HR; Huntsman DG; Karnezis AN; Köbel M; Menon U; Pharoah PDP; Doherty JA; Anglesio MS; Pike MC; Pearce CL; Friedlander ML; DeFazio A; Nelson BH; Ramus SJ, 2023, 'Profiling the immune landscape in mucinous ovarian carcinoma', Gynecologic Oncology, 168, pp. 23 - 31, http://dx.doi.org/10.1016/j.ygyno.2022.10.022

Smith D; Robledo KP; Yip S; Cummins MM; Kok PS; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Spurdle AB; Andrews J; Stockler MR; Mileshkin L; Antill Y, 2023, 'Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)', Cancers, 15, http://dx.doi.org/10.3390/cancers15010254

Kumari S; Moujaber T; Madsen I; Gao B; Provan P; Srirangan S; Bouantoun N; Kennedy C; Sharma R; Fereday S; Traficante N; Friedlander ML; Brand A; Gourley C; Garsed DW; Bowtell D; Balleine R; Harnett P; DeFazio A, 2023, '16P Response to taxanes in low-grade serous ovarian cancer patients and cell lines', ESMO Open, 8, pp. 101037 - 101037, http://dx.doi.org/10.1016/j.esmoop.2023.101037

Friedlander M; Lee YC; Tew WP, 2023, 'Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.', Am Soc Clin Oncol Educ Book, 43, pp. e390876, http://dx.doi.org/10.1200/EDBK_390876

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See M-L; Moore KN, 2023, 'Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical & Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/ogx.0000000000001120

Campbell R; King MT; Stockler MR; Lee YC; Roncolato FT; Friedlander ML, 2023, 'Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.', Patient Relat Outcome Meas, 14, pp. 111 - 126, http://dx.doi.org/10.2147/PROM.S297301

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubinski J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F, 2022, 'Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes', Clinical Cancer Research, 28, pp. 5383 - 5395, http://dx.doi.org/10.1158/1078-0432.CCR-22-1206

Back to profile page